[6]Binghe Xu,Qingyuan Zhang,Pin Zhang,et al.Dalpiciclib plus letrozole or anastrozole as 1st-line treatment for HR+/HER2-advanced breast cancer(DAWNA-2):a phase 3 trial.2022 ESMO.LBA16. [7]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2021年版).中国癌症杂志.2021;31(10)...
[2]Chen Z, Ouyang Q, Wang Y, et al. Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China. Front Oncol. 2022 Mar 3;12:829693. [3] Rugo HS, Finn RS, Diéras V, et al. Palbociclib...
2024年5月,复旦大学附属肿瘤医院吴炅教授团队在《Cancer Treatment Reviews》(影响因子为11.8)发表了一篇综述,题为《Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use...
[4].Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, et al. Firstline treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positivemetastatic breast cancer from registHER. Oncologist 2013;18:501–10.[5].Rimawi M, Ferrero JM, de la Ha...
breast cancer and the second one is related to the use of immune checkpoint inhibitors in the area of HR positive HER2 negativeearly breast cancer. Doingphysical activity is the best way to prevent cancer recurrence and to improve the quality of life while during treatment in the adjuvant ...
25、Hope S.Rugo et al.Trastuzumab deruxtecan(T-DXd)vs treatment of physician’s choice(TPC)in patients(pts)with HER2-low unresectable and/or metastatic breast cancer(mBC):a detailed safety analysis of the randomized,phase 3 DESTINY-Breast04 trial.2023 ESMO BC Abstract 185O. ...
HR+/HER2+ 晚期乳腺癌(Advanced Breast Cancer,ABC),指南推荐一线治疗方案需含抗HER-2靶向治疗。通常将内分泌治疗用于无法耐受化疗的患者,或作为化疗后的维持治疗。 「去化疗」一直是 HR+/HER2+ ABC 临床探索的方向,随着新兴药物的面世、循证医学数据的累积...
16.Binghe Xu, et al. FRIEND study: Efficacy and safety of first line therapy with fulvestrant or exemestane for postmenopausal ER+/HER2 advanced breast cancer patients after adjuvant non steroidal aromatase inhibitor treatment: A randomized, open label, multicenter study. ESMO 2021. 2021Sep; Abstrac...
7. Taylor-Stokes G, Mitra D, Waller J, et al. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR /HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS st...
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR , HER2-, Node-Positive, High-Risk, Early Breast Cancer (MonarchE). J Clin Oncol. 2020;38(34):3987-3998. 特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。